SLU-PP-332
Molecular Identifiers
Overview
Novel metabolic compound. ERRα/γ agonist with exercise mimetic properties. Research ongoing. Follow specific study protocols.
Interest in SLU-PP-332 stems from its profile as an exercise mimetic: by agonizing the ERRα and ERRγ receptors, it activates transcriptional programs associated with physical exercise, increasing mitochondrial oxidative capacity and the expression of type IIa muscle fiber genes. In preclinical research, this mechanism translates into better endurance and a more favorable metabolic profile without the animal having to exercise.
It is not a peptide but a small molecule still confined to the research setting. There is no regulatory approval or human clinical indication, and the compound is not dispensed by compounding pharmacies for therapeutic use. Recreational use among performance enthusiasts remains experimental, with no long-term safety data.
Small molecule — synthetic ERR (estrogen-related receptor) agonist, not a peptide
Half-life
~4-8 hours
Administration Route
Oral or subcutaneous
Category
Metabolic & Fat Loss
Mechanism of Action
- ERRα and ERRγ receptor agonism
- Activation of muscle exercise programs
- Improvement of mitochondrial oxidative capacity
- Increased type IIa (fast oxidative) muscle fiber gene expression
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Gastrointestinal discomfort
- Transient fatigue
- Mild headache
Product Properties
| Purity | >98% |
| Appearance | White to off-white powder |
| Solubility | Soluble in DMSO; limited aqueous solubility |
| Source | Chemical synthesis |
| Storage | Room temperature (15-25°C) desiccated for up to 2 years. Protect from moisture and light. |
Presentations & Preparation
Vials of SLU-PP-332 found in the research market:
Reconstitution
- Diluent: Per protocol
- Volume: Per protocol
- Follow specific study protocol
Storage
- Lyophilized: -20°C
- Reconstituted: Per protocol
- Compound in active research phase
Scientific Studies
Published studies on SLU-PP-332.
A Synthetic ERR Agonist Alleviates Metabolic Syndrome
Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler AA, Elgendy B, Walker JK, Burris TP
Synthetic ERRalpha/beta/gamma Agonist Induces an ERRalpha-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, Kazantzis M, et al.
Related Peptides
5-Amino-1MQ
50 mg per capsule · 1-2 times daily
Adipotide
0.03 mg/kg body weight (Phase 1 trial starting dose) · Once daily
AICAR
0.1 mg/kg/min by intravenous infusion (CABG trial dose) · Single continuous infusion
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly